| Nov 15 |
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet
|
| Nov 13 |
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
|
| Nov 11 |
Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),
|
| Nov 7 |
Monte Rosa Therapeutics GAAP EPS of -$0.29
|
| Nov 7 |
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 7 |
Monte Rosa Therapeutics: Q3 Earnings Snapshot
|
| Nov 7 |
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 6 |
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice
|
| Oct 30 |
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade
|
| Oct 29 |
Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler
|
